발 및 발목 오소바이오로직스 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Foot And Ankle Orthobiologics Market Summary

The global foot and ankle orthobiologics market size was estimated at USD 746.44 million in 2024 and is projected to reach USD 1.47 billion by 2033, growing at a CAGR of 7.87% from 2025 to 2033. The growing burden of osteoporosis and degenerative disorders is one of the key factors driving the growth of the market.

According to the Oxford University Press article published in June 2025, from around 256 million people in 1990 to over 600 million in 2021 had osteoarthritis, with projections nearing 765 million by 2060 has created significant pressure on healthcare systems to deliver more effective musculoskeletal treatments. As foot and ankle joints are often among the first to experience degenerative changes, the demand for biologic interventions such as demineralized bone matrix, allografts, bone morphogenetic proteins, and stem cell therapies is rising, as these options support joint preservation and bone healing.

Moreover, as per the Elsevier B.V. article published in September 2024, ankle osteoarthritis, though less common than knee or hip disease, affects nearly 1% of adults worldwide and represents about 3% of all osteoarthritis cases, with an incidence of roughly 30 per 100,000 people. Its impact on mobility and quality of life is substantial, often leading to pain, stiffness, and functional decline that require medical intervention. For many of these patients, biologic options such as demineralized bone matrix, allografts, bone morphogenetic proteins, and stem cell therapies are being utilized to promote bone healing and joint preservation. At the same time, wedges including viscosupplementation and synthetic bone substitutes are increasingly applied to reduce joint stress and delay more invasive procedures. Hospitals typically manage advanced cases through reconstructive surgeries, while outpatient clinics are adopting injectable and minimally invasive biologic therapies for earlier stages. This rising clinical burden of ankle osteoarthritis is therefore directly fueling the adoption of both biologic and wedge-based orthobiologic solutions across care settings.

Global Foot And Ankle Orthobiologics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes industry trends in each sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the global foot and ankle orthobiologics market report based on product, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
  • Demineralized Bone Matrix (DBM)
  • Allograft
  • Bone Morphogenetic Protein(BMP)
  • Stem Cell
• Wedges
  • Viscosupplementation
  • Synthetic Bone Substitutes
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Clinics
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Spain
  • Italy
  • France
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Foot and Ankle Orthobiologics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of osteoarthritis and degenerative disease
    • 3.2.1.2. Rising number of sport injuries
    • 3.2.1.3. Growing number of road traffic accidents
    • 3.2.1.4. Technological advancements in foot and ankle orthobiologics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulatory approval processes
    • 3.2.2.2. High treatment costs
    • 3.2.2.3. Limited reimbursement policies
• 3.3. Foot and Ankle Orthobiologics: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Regulatory Framework
• 3.5. Technology Advancement in the Foot and Ankle Orthobiologics Market
• 3.6. Investment and Funding Scenario in the Foot and Ankle Orthobiologics Market

Chapter 4. Foot and Ankle Orthobiologics Market Segment Analysis, By Product, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Foot and Ankle Orthobiologics Market, by Product, 2021 to 2033
• 4.5. Biologics
  • 4.5.1. Biologics market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5.2. Demineralized Bone Matrix (DBM)
    • 4.5.2.1. Demineralized Bone Matrix (DBM) market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5.3. Allograft
    • 4.5.3.1. Allograft market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5.4. Bone Morphogenetic Protein(BMP)
    • 4.5.4.1. Bone Morphogenetic Protein(BMP) market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5.5. Stem Cell
    • 4.5.5.1. Stem Cell market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Wedges
  • 4.6.1. Wedges market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.2. Viscosupplementation
    • 4.6.2.1. Viscosupplementation market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.3. Synthetic Bone Substitutes
    • 4.6.3.1. Synthetic Bone Substitutes market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Foot and Ankle Orthobiologics Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. End Use Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Foot and Ankle Orthobiologics Market, by End Use, 2021 to 2033
• 5.5. Hospitals
  • 5.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Outpatient Clinics
  • 5.6.1. Outpatient clinics market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Foot and Ankle Orthobiologics Market Segment Analysis, By Region, By Product, By End Use, 2021 - 2033 (USD Million)

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Regional Market Snapshot
• 6.4. Foot and Ankle Orthobiologics Market Share by Region, 2024 & 2033:
• 6.5. North America
  • 6.5.1. North America foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory Scenario
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. U.S. foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory Scenario
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. Canada foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory Scenario
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Mexico foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.2. UK
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory Scenario
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. UK foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Germany foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory Scenario
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. France foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory Scenario
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Italy foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory Scenario
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Spain foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.7. Norway
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory Scenario
    • 6.6.7.3. Competitive Scenario
    • 6.6.7.4. Norway foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory Scenario
    • 6.6.8.3. Competitive Scenario
    • 6.6.8.4. Sweden foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.6.9. Denmark
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory Scenario
    • 6.6.9.3. Competitive Scenario
    • 6.6.9.4. Denmark foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory Scenario
    • 6.7.1.3. Competitive Scenario
    • 6.7.1.4. Japan foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory Scenario
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. China foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory Scenario
    • 6.7.3.3. Competitive Scenario
    • 6.7.3.4. India foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory Scenario
    • 6.7.4.3. Competitive Scenario
    • 6.7.4.4. Australia foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory Scenario
    • 6.7.5.3. Competitive Scenario
    • 6.7.5.4. South Korea foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory Scenario
    • 6.7.6.3. Competitive Scenario
    • 6.7.6.4. Thailand foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory Scenario
    • 6.8.1.3. Competitive Scenario
    • 6.8.1.4. Brazil foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory Scenario
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. Argentina foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory Scenario
    • 6.9.1.3. Competitive Scenario
    • 6.9.1.4. South Africa foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory Scenario
    • 6.9.2.3. Competitive Scenario
    • 6.9.2.4. Saudi Arabia foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory Scenario
    • 6.9.3.3. Competitive Scenario
    • 6.9.3.4. UAE foot and ankle orthobiologics market, 2021 - 2033 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory Scenario
    • 6.9.4.3. Competitive Scenario
    • 6.9.4.4. Kuwait foot and ankle orthobiologics market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Profiles
  • 7.3.1. Medtronic
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Johnson & Johnson (DePuy Synthes)
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Zimmer Biomet
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Stryker Corporation
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Orthofix, Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Arthrex, Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Smith & Nephew
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Integra LifeSciences
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Acumed
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Bioventus
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives